Oncolytic virus therapy
A method of treating a human subject with cancer is disclosed. A pharmaceutical composition is administered to the subject, the pharmaceutical composition comprising human leukocytes and a replication-competent oncolytic virus in suspension in a physiologically acceptable solution. Alternatively the pharmaceutical composition comprises human leukocytes or platelets infected with an oncolytic virus.
1. A method of treating a human subject with cancer, comprising administering to the subject an amount of a pharmaceutical composition effective to treat the subject, the pharmaceutical composition comprising human leukocytes and a replication-competent oncolytic virus in suspension in a physiologically acceptable solution, wherein
the leukocytes comprise monocytes;
the virus binds to the monocytes; and
the ratio of plaque-forming units of the virus to number of monocytes in the composition is at least 1:100,
thereby treating the subject.
2. The method of claim 1 , wherein the monocytes are monocytes of the subject.
3. The method of claim 1 , wherein the monocytes are monocytes of a donor other than the subject.
4. The method of claim 1 , wherein the monocytes are cultured.
5. The method of claim 1 , wherein the monocytes are not cultured.
6. The method of claim 1 , wherein the monocytes have been incubated with the virus for about 30 minutes prior to the administering.
7. The method of claim 1 , wherein the leukocytes are leukocytes isolated by leukophoresis.
8. The method of claim 1 , wherein the leukocytes comprise neutrophils.
9. The method of claim 1 , wherein the leukocytes comprise lymphocytes.
10. The method of claim 9 , wherein the lymphocytes are tumor-infiltrating lymphocytes.
11. The method of claim 1 , wherein the virus is a clonal virus.
12. The method of claim 1 , wherein the virus is selected from the group consisting of a mumps virus, a measles virus, a vesicular stomatitis virus, a para-influenza virus, an influenza virus, an adenovirus, a herpes I virus, a vaccinia virus, and a reovirus.
13. The method of claim 1 , wherein the virus is a Newcastle disease virus.
14. The method of claim 1 , wherein the virus is a Newcastle disease virus of moderate virulence.
15. The method of claim 1 , wherein the composition is administered intravenously.
16. The method of claim 1 , wherein the composition is administered intratumorally.
17. The method of claim 1 , wherein the composition is administered intraperitoneally.
18. The method of claim 1 , wherein the ratio of plaque-forming units of the virus to number of leukocytes in the composition is at least 1:1.
19. The method of claim 13 , wherein the ratio of plaque-forming units of the virus to number of leukocytes in the composition is between about 1:1 to about 200:1.
20. The method of claim 13 , wherein the ratio of plaque-forming units of the virus to number of leukocytes in the composition is about 200:1.
21. A method of treating a human subject with cancer, comprising administering to the subject an amount of a pharmaceutical composition effective to treat the subject, the pharmaceutical composition comprising human cells and an oncolytic virus in suspension in a physiologically acceptable solution, wherein the cells are leukocytes or platelets, thereby treating the subject.
22. The method of claim 21 , wherein the cells are cells of the subject.
23. The method of claim 21 , wherein the leukocytes are monocytes.
24. The method of claim 21 , wherein the pharmaceutical composition comprises whole blood containing leukocytes or platelets infected with the virus.